Thomas Pabst
Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data.
Arber C, Baerlocher G, Chalandon Y, Daskalakis M, Duchosal M, Fehr M, Gerull S, Güngör T, Nair G, Pabst T, Passweg J, Piccolruaz B, Renner C, Rüfer A, Schneidawind D, Stuessi G, Zeerleder S, Halter J, Swiss Blood Stem Cell Transplant and Cellular Therapies (SBST) group. Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly 2024; 154:3704.
03.10.2024Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data.
03.10.2024Swiss Med Wkly 2024; 154:3704
Arber Caroline, Baerlocher Gabriela M, Chalandon Yves, Daskalakis Michael, Duchosal Michel A, Fehr Martin, Gerull Sabine, Güngör Tayfun, Nair Gayathri, Pabst Thomas, Passweg Jakob R, Piccolruaz Barbara, Renner Christoph, Rüfer Axel, Schneidawind Dominik, Stuessi Georg, Zeerleder Sacha, Halter Jörg P, Swiss Blood Stem Cell Transplant and Cellular Therapies (SBST) group
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
Passweg J, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, Diepold M, Diesch-Furlanetto T, Duchosal M, Gerull S, Güngör T, Heim D, Hitz F, Holbro A, Masouridi-Levrat S, Nair G, Novak U, Pabst T, Renner C, Stussi G, Schneidawind D, Schanz U, Wannesson L, Halter J, Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021. Hematol Oncol 2023
06.12.2023Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
06.12.2023Hematol Oncol 2023
Passweg Jakob R, Baldomero Helen, Ansari Marc, Arber Caroline, Chalandon Yves, Daskalakis Michael, Diepold Miriam, Diesch-Furlanetto Tamara, Duchosal Michel A, Gerull Sabine, Güngör Tayfun, Heim Dominik, Hitz Felicitas, Holbro Andreas, Masouridi-Levrat Stavroula, Nair Gayathri, Novak Urban, Pabst Thomas, Renner Christoph, Stussi Georg, Schneidawind Dominik, Schanz Urs, Wannesson Luciano, Halter Jörg P, Swiss Blood Stem Cell Transplantation Group (SBST)
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Hilberink J, van Zeventer I, Chitu D, Pabst T, Klein S, Stussi G, Griskevicius L, Valk P, Cloos J, van de Loosdrecht A, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz M, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel M, Legdeur M, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele G, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls G. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood Cancer J 2023; 13:93.
19.06.2023Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
19.06.2023Blood Cancer J 2023; 13:93
Hilberink Jacobien R, van Zeventer Isabelle A, Chitu Dana A, Pabst Thomas, Klein Saskia K, Stussi Georg, Griskevicius Laimonas, Valk Peter J M, Cloos Jacqueline, van de Loosdrecht Arjan A, Breems Dimitri A, van Lammeren-Venema Daniëlle, Boersma Rinske, Jongen-Lavrencic Mojca, Fehr Martin, Hoogendoorn Mels, Manz Markus G, Söhne Maaike, van Marwijk Kooy Rien, Deeren Dries, van der Poel Marjolein W M, Legdeur Marie-Cecile J C, Tick Lidwine W, Chalandon Yves, Ammatuna Emanuele, Blum Sabine, Löwenberg Bob, Ossenkoppele Gert J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls Gerwin
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia 2023; 37:699-701.
12.01.2023Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
12.01.2023Leukemia 2023; 37:699-701
Zander Thilo, Pabst Thomas, Schär Sämi, Aebi Stefan, Mey Ulrich J M, Novak Urban, Lerch Erika, Rhyner Agocs Gaëlle, Goede Jeroen, Maniecka Zuzanna, Hayoz Stefanie, Rüfer Axel, Renner Christoph, Driessen Christoph
Absence of Susceptibility Vessel Sign in Patients With Malignancy-Related Acute Ischemic Stroke Treated With Mechanical Thrombectomy.
Beyeler M, Belachew N, Kielkopf M, Aleman E, León Betancourt A, Genceviciute K, Kurmann C, Grunder L, Birner B, Meinel T, Scutelnic A, Bücke P, Seiffge D, Dobrocky T, Piechowiak E, Pilgram-Pastor S, Mattle H, Mordasini P, Arnold M, Fischer U, Pabst T, Gralla J, Seeberger M, Jung S, Kaesmacher J. Absence of Susceptibility Vessel Sign in Patients With Malignancy-Related Acute Ischemic Stroke Treated With Mechanical Thrombectomy. Front Neurol 2022; 13:930635.
14.07.2022Absence of Susceptibility Vessel Sign in Patients With Malignancy-Related Acute Ischemic Stroke Treated With Mechanical Thrombectomy.
14.07.2022Front Neurol 2022; 13:930635
Beyeler Morin, Belachew Nebiyat Filate, Kielkopf Moritz, Aleman Enrique B, León Betancourt Alejandro Xavier, Genceviciute Kotryna, Kurmann Christoph C, Grunder Lorenz, Birner Barbara, Meinel Thomas Raphael, Scutelnic Adrian, Bücke Philipp, Seiffge David Julian, Dobrocky Tomas, Piechowiak Eike Immo I, Pilgram-Pastor Sara M, Mattle Heinrich Paul, Mordasini Pasquale, Arnold Marcel, Fischer Urs, Pabst Thomas, Gralla Jan, Seeberger Manfred Daniel, Jung Simon, Kaesmacher Johannes
Development of a Score for Prediction of Occult Malignancy in Stroke Patients (Occult-5 Score).
Beyeler M, Birner B, Branca M, Meinel T, Vynckier J, Buffle E, Scutelnic A, Heldner M, Bücke P, Seiffge D, Mordasini P, Dobrocky T, Piechowiak E, Kaesmacher J, Gralla J, Mattle H, Arnold M, Fischer U, Pabst T, Berger M, Jung S. Development of a Score for Prediction of Occult Malignancy in Stroke Patients (Occult-5 Score). J Stroke Cerebrovasc Dis 2022; 31:106609.
23.06.2022Development of a Score for Prediction of Occult Malignancy in Stroke Patients (Occult-5 Score).
23.06.2022J Stroke Cerebrovasc Dis 2022; 31:106609
Beyeler Morin, Birner Barbara, Branca Mattia, Meinel Thomas Raphael, Vynckier Jan, Buffle Eric, Scutelnic Adrian, Heldner Mirjam R, Bücke Philipp, Seiffge David Julian, Mordasini Pasquale, Dobrocky Tomas, Piechowiak Eike Immo, Kaesmacher Johannes, Gralla Jan, Mattle Heinrich Paul, Arnold Marcel, Fischer Urs, Pabst Thomas, Berger Martin D, Jung Simon
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
Kreissl S, Keller U, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Bentz M, Hitz F, Topp M, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, German Hodgkin Study Group. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021; 8:e398-e409.
01.06.2021PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
01.06.2021Lancet Haematol 2021; 8:e398-e409
Kreissl Stefanie, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Diehl Volker, Dietlein Markus, Engert Andreas, Borchmann Peter, Bentz Martin, Hitz Felicitas, Topp Max S, Goergen Helen, Buehnen Ina, Kobe Carsten, Moccia Alden, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, German Hodgkin Study Group
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
Brune M, Cogliatti S, Ossenkoppele G, Löwenberg B, Rudolf C, Li Q, Passweg J, Mazzuchelli L, Medinger M, Tzankov A, Fehr M, Grobholz R, Stussi G, Lundberg P, Vela V, Heim D, Manz M, Haralambieva E, Pabst T, Banz Y, Bargetzi M, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Ann Hematol 2021; 100:1169-1179.
02.03.2021Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
02.03.2021Ann Hematol 2021; 100:1169-1179
Brune Magdalena M, Cogliatti Sergio B., Ossenkoppele Gert J, Löwenberg Bob, Rudolf Christina Biaggi, Li Qiyu, Passweg Jakob, Mazzuchelli Luca, Medinger Michael, Tzankov Alexandar, Fehr Martin, Grobholz Rainer, Stussi Georg, Lundberg Pontus, Vela Visar, Heim Dominik, Manz Markus G, Haralambieva Eugenia, Pabst Thomas, Banz Yara, Bargetzi Mario, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Ossenkoppele G, Pabst T, Oosterveld M, Obbergh F, Nijziel M, Moors I, Kooy M, Maertens J, Loosdrecht A, Legdeur M, Poel M, Sinnige H, Spertini O, Norden Y, Stussi G, Westerweel P, Weerdt O, Vellenga E, Vekemans M, Velden W, Tick L, Terpstra W, Lammeren-Venema D, Kuball J, Deeren D, Chalandon Y, Brouwer R, Breems D, Borne P, Biemond B, Bargetzi M, Manz M, Löwenberg B, Efthymiou A, Gjertsen B, Graux C, Klift M, Klein S, Jongen-Lavrencic M, Jie A, Jaspers A, Hoogendoorn M, Hess U, Heim D, Gregor M, Janssen J. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers (Basel) 2021; 13
07.02.2021Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
07.02.2021Cancers (Basel) 2021; 13
Ossenkoppele Gert, Pabst Thomas, Oosterveld Margriet, Obbergh Florence van, Nijziel Marten, Moors Ine, Kooy Marinus van Marwijk, Maertens Johan, Loosdrecht Arjan van de, Legdeur Marie-Cecile, Poel Marjolein van der, Sinnige Harm, Spertini Olivier, Norden Yvette van, Stussi Georg, Westerweel Peter, Weerdt Okke de, Vellenga Edo, Vekemans Marie-Christiane, Velden Walter van der, Tick Lidwine, Terpstra Wim, Lammeren-Venema Danielle van, Kuball Jurgen, Deeren Dries, Chalandon Yves, Brouwer Rolf, Breems Dimitri, Borne Peter von dem, Biemond Bart, Bargetzi Mario, Manz Markus, Löwenberg Bob, Efthymiou Anna, Gjertsen Bjørn-Tore, Graux Carlos, Klift Marjolein van der, Klein Saskia, Jongen-Lavrencic Mojca, Jie Asiong, Jaspers Aurelie, Hoogendoorn Mels, Hess Urs, Heim Dominik, Gregor Michael, Janssen Jeroen
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Ossenkoppele G, Porkka K, Cornelissen J, Kuball J, Fischer T, Legdeur M, Hoogendoorn M, Breems D, Moors I, van Lammeren-Venema D, Silzle T, Juliusson G, Meyer P, Floisand Y, Manz M, van Elssen C, Valk P, Cloos J, Passweg J, Huls G, Janssen J, Gjertsen B, Höglund M, Gregor M, Veelken H, van Marwijk Kooy M, Jongen-Lavrencic M, Tick L, Griskevicius L, Vellenga E, Spertini O, Biemond B, Gradowska P, Maertens J, Pabst T, Vekemans M, van der Velden W, Westerweel P, Gadisseur A, Klein S, Bargetzi M, van Esser J, de Weerdt O, Deeren D, Graux C, Michaux L, Beverloo B, Löwenberg B. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv 2021; 5:1110-1121.
23.01.2021Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
23.01.2021Blood Adv 2021; 5:1110-1121
Ossenkoppele Gert J, Porkka Kimmo, Cornelissen Jan, Kuball Juergen, Fischer Thomas, Legdeur Marie-Cecile J C, Hoogendoorn Mels, Breems Dimitri A, Moors Ine, van Lammeren-Venema Daniëlle, Silzle Tobias, Juliusson Gunnar, Meyer Peter, Floisand Yngvar, Manz Markus G, van Elssen Catharina H M J, Valk Peter J M, Cloos Jacqueline, Passweg Jakob, Huls Gerwin, Janssen Jeroen J W M, Gjertsen Bjorn T, Höglund Martin, Gregor Michael, Veelken Hendrik, van Marwijk Kooy Marinus, Jongen-Lavrencic Mojca, Tick Lidwine W, Griskevicius Laimonas, Vellenga Edo, Spertini Olivier, Biemond Bart J, Gradowska Patrycja, Maertens Johan, Pabst Thomas, Vekemans Marie-Christiane, van der Velden Walter J F M, Westerweel Peter E, Gadisseur Alain, Klein Saskia K, Bargetzi Mario, van Esser Joost W J, de Weerdt Okke, Deeren Dries, Graux Carlos, Michaux Lucienne, Beverloo Berna, Löwenberg Bob
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
Moccia A, Rauch D, Vorobiof D, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Raats J, Del Giglio A, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Zucca E. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Adv 2020; 4:5951-5957.
08.12.2020Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
08.12.2020Blood Adv 2020; 4:5951-5957
Moccia Alden A, Rauch Daniel, Vorobiof Daniel A, Lohri Andreas, Ruegsegger Céline, Biaggi Rudolf Christine, Rusterholz Corinne, Hayoz Stefanie, Ghielmini Michele, Raats Johann, Del Giglio Auro, Taverna Christian, Schär Sämi, Vanazzi Anna, Rondeau Stephanie, Hitz Felicitas, Mingrone Walter, Pabst Thomas, Cevreska Lidija, Zucca Emanuele
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Benz R, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Feller A, Rauch D, Blum S, Mey U, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Stussi G. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv 2020; 4:3699-3707.
11.08.2020Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
11.08.2020Blood Adv 2020; 4:3699-3707
Benz Rudolf, O'Meara Stern Alix, Cantoni Nathan, Bargetzi Mario, Bianchi-Papina Elena, Rossi Davide, Passweg Jakob, Lohri Andreas, Berardi Simona, Feller Anita, Rauch Daniel, Blum Sabine, Mey Ulrich, Arn Kornelius, Andres Martin, Pabst Thomas, Baumann Michael, Novak Urban, Hitz Felicitas, Hess Urs, Zenhaeusern Reinhard, Chalandon Yves, Stussi Georg
Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Schmidt A, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Heim D, Duchosal M, Driessen C, Betticher D, Bargetzi M, Renner C. Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2019; 149:w20031.
03.04.2019Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
03.04.2019Swiss Med Wkly 2019; 149:w20031
Samaras Panagiotis, Zander Thilo, Taverna Christian, Schmidt Adrian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Heim Dominik, Duchosal Michel A, Driessen Christoph, Betticher Daniel C, Bargetzi Mario, Renner Christoph
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Ghilardi G, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg J, Stussi G, Kleber M, Gerber B, Rossi D, Schmidt A, Pabst T, Jeker B, Müller R, Cairoli A, Müller A, Bargetzi M, Hitz F, Baldomero H, Heim D, Swiss Blood Stem Cell Transplantation Registry. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplant 2018
02.11.2018Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
02.11.2018Bone Marrow Transplant 2018
Ghilardi Guido, Ghielmini Michele, Wannesson Luciano, Lerch Erika, Samaras Panagiotis, Schanz Urs, Passweg Jakob R, Stussi Georg, Kleber Martina, Gerber Bernhard, Rossi Davide, Schmidt Adrian, Pabst Thomas, Jeker Barbara, Müller Rouven, Cairoli Anne, Müller Antonia M S, Bargetzi Mario, Hitz Felicitas, Baldomero Helen, Heim Dominik, Swiss Blood Stem Cell Transplantation Registry
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
20.09.2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
20.09.2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016
Passweg J, Masouridi-Levrat S, Müller A, Nair G, Pabst T, Renner C, Schmidt A, Stussi G, Nicoloso de Faveri G, Schanz U, Leibundgut K, Hess U, Heim D, Baldomero H, Ansari M, Baerlocher G, Bargetzi M, Chalandon Y, Duchosal M, Gerull S, Güngör T, Halter J, For The Swiss Blood Stem Cell Transplantation Group Sbst. Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016. Swiss Med Wkly 2018; 148:w14589.
01.03.2018Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016
01.03.2018Swiss Med Wkly 2018; 148:w14589
Passweg Jakob R, Masouridi-Levrat Stavroula, Müller Antonia, Nair Gayathri, Pabst Thomas, Renner Christoph, Schmidt Adrian, Stussi Georg, Nicoloso de Faveri Grazia, Schanz Urs, Leibundgut Kurt, Hess Urs, Heim Dominik, Baldomero Helen, Ansari Marc, Baerlocher Gabriela M, Bargetzi Mario, Chalandon Yves, Duchosal Michel A, Gerull Sabine, Güngör Tayfun, Halter Jörg P, For The Swiss Blood Stem Cell Transplantation Group Sbst
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017; 390:2790-2802.
20.10.2017PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
20.10.2017Lancet 2017; 390:2790-2802
Borchmann Peter, Bentz Martin, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Schmitz Norbert, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Kuhnert Georg, Diehl Volker, Dietlein Markus, Hitz Felicitas, Topp Max S, Goergen Helen, Kobe Carsten, Lohri Andreas, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Hüttmann Andreas, Dierlamm Judith, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, Engert Andreas
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma
Ribi K, Rondeau S, Hitz F, Mey U, Enoiu M, Pabst T, Stathis A, Fischer N, Clough-Gorr K. Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma. Support Care Cancer 2017; 25:2833-2842.
13.04.2017Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma
13.04.2017Support Care Cancer 2017; 25:2833-2842
Ribi Karin, Rondeau Stephanie, Hitz Felicitas, Mey Ulrich, Enoiu Milica, Pabst Thomas, Stathis Anastasios, Fischer Natalie, Clough-Gorr Kerri M
Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison
Baumgartner A, Mueller B, Stanga Z, Hess U, Duchosal M, Pabst T, Wannesson L, Limonta A, Pichard C, Chalandon Y, Samaras P, Schanz U, Passweg J, Medinger M, Zueger N, Bargetzi A, Bargetzi M, Schuetz P. Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. Nutrition 2016; 35:43-50.
15.10.2016Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison
15.10.2016Nutrition 2016; 35:43-50
Baumgartner Annic, Mueller Beat, Stanga Zeno, Hess Urs, Duchosal Michel A, Pabst Thomas, Wannesson Luciano, Limonta Alessandro, Pichard Claude, Chalandon Yves, Samaras Panagiotis, Schanz Urs, Passweg Jakob, Medinger Micheal, Zueger Noemi, Bargetzi Annika, Bargetzi Mario, Schuetz Philipp
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Hitz F, Rondeau S, Berardi Vilei S, Eckhardt K, Enoiu M, Rothermundt C, Schmidt A, Krasniqi F, Mach N, Caspar C, Samaras P, Cairoli A, Fischer N, Pabst T, Zucca E, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol 2016
28.03.2016Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
28.03.2016Br J Haematol 2016
Hitz Felicitas, Rondeau Stephanie, Berardi Vilei Simona, Eckhardt Katrin, Enoiu Milica, Rothermundt Christian, Schmidt Adrian, Krasniqi Fatime, Mach Nicolas, Caspar Clemens B, Samaras Panagiotis, Cairoli Anne, Fischer Natalie, Pabst Thomas, Zucca Emanuele, Mey Ulrich